Scarica l'app Stockscreener
7.26
2.68%
-0.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.46
Aprire:
$7.47
Volume 24 ore:
1.14M
Relative Volume:
0.97
Capitalizzazione di mercato:
$565.88M
Reddito:
$400.05M
Utile/perdita netta:
$181.01M
Rapporto P/E:
3.4583
EPS:
2.0993
Flusso di cassa netto:
$194.58M
1 W Prestazione:
-1.63%
1M Prestazione:
-7.16%
6M Prestazione:
+1.82%
1 anno Prestazione:
-27.98%
Intervallo 1D:
$7.235
$7.47
Intervallo di 1 settimana:
$7.1568
$7.695
Portata 52W:
$6.125
$13.02
Cormedix Inc Stock (CRMD) Company Profile
Nome
Cormedix Inc
Settore
Industria
Telefono
908-517-9500
Indirizzo
389 INTERPACE PKWY, SUITE 450, PARSIPPANY
Compare CRMD vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRMD
Cormedix Inc
|
7.26 | 565.88M | 400.05M | 181.01M | 194.58M | 2.0993 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cormedix Inc Stock (CRMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-23 | Iniziato | Oppenheimer | Outperform |
| 2025-10-20 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2025-06-30 | Downgrade | D. Boral Capital | Buy → Hold |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Leerink Partners | Outperform |
| 2025-01-13 | Iniziato | D. Boral Capital | Buy |
| 2024-08-26 | Iniziato | Rodman & Renshaw | Buy |
| 2023-08-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-02-17 | Iniziato | Needham | Buy |
| 2020-09-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-09-21 | Iniziato | Truist | Buy |
| 2019-12-18 | Iniziato | B. Riley FBR | Buy |
| 2019-03-26 | Reiterato | H.C. Wainwright | Buy |
| 2018-12-06 | Iniziato | ROTH Capital | Buy |
| 2017-09-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-08-10 | Reiterato | Rodman & Renshaw | Buy |
| 2017-05-05 | Reiterato | Rodman & Renshaw | Buy |
| 2016-11-11 | Reiterato | FBR & Co. | Outperform |
| 2016-03-17 | Reiterato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | FBR Capital | Outperform |
| 2015-11-16 | Reiterato | ROTH Capital | Neutral |
| 2015-10-29 | Reiterato | ROTH Capital | Neutral |
| 2015-05-06 | Downgrade | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Reiterato | ROTH Capital | Buy |
| 2011-10-03 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Cormedix Inc Borsa (CRMD) Ultime notizie
RBC Capital Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $14 - Moomoo
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now? - Zacks Investment Research
CorMedix (NASDAQ: CRMD) Strengthens Its Commercial Growth Story - kalkine.ca
US218939AB27 Bond Yield and Price — BONDSCOM:US218939AB27 - TradingView
(CRMD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
CorMedix Inc (NASDAQ:CRMD) Stock Now Rated "Moderate Buy" by Wall Street Analysts - MarketBeat
150,656 Shares in CorMedix Inc $CRMD Acquired by Bank of America Corp DE - MarketBeat
CorMedix Inc. R (19KA.F) Q1 FY2026 earnings call transcript - Yahoo Finance
Diluted net income available to common stockholders of CorMedix Inc. – HAN:19KA - TradingView
Non-operating income (total) of CorMedix Inc. – HAN:19KA - TradingView
Price to cash flow ratio of CorMedix Inc. – HAN:19KA - TradingView
Cash flow from financing activities of CorMedix Inc. – HAN:19KA - TradingView
ETFs Investing in CorMedix Inc. Stocks - TradingView
CorMedix Inc. Balance Sheet – HAN:19KA - TradingView
Return on assets % of CorMedix Inc. – HAN:19KA - TradingView
Enterprise value of CorMedix Inc. – HAN:19KA - TradingView
CorMedix Inc. Revenue Breakdown – HAN:19KA - TradingView
Form 4 CorMedix Inc For: 27 September - Investing.com India
Form 4 CorMedix Inc For: 27 September By Investing.com - Investing.com Australia
Form 4 CorMedix Inc For: 27 September By Investing.com - Investing.com Nigeria
Form 4 CorMedix Inc For: 27 September By Investing.com - Investing.com UK
Is CRMD Stock a Buy Now After Strong Growth and New Risks? - Eastern Progress
The Technical Signals Behind (CRMD) That Institutions Follow - Stock Traders Daily
Cormedix Inc Lobbying Profile, 2015 - OpenSecrets
CorMedix (NASDAQ:CRMD) Shares Gap UpStill a Buy? - MarketBeat
CRMD Shareholder Alert: Rosen, a Longstanding and Trusted Firm, Encourages CorMedix Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionCRMD - TMX Newsfile
Oppenheimer Initiates CorMedix at Outperform With $15 Price Target - Moomoo
Oppenheimer Initiates CorMedix at Outperform With $15 Price Target - marketscreener.com
CorMedix (NASDAQ:CRMD) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Oppenheimer initiates CorMedix stock coverage with outperform rating - Investing.com
CorMedix Inc. (CRMD) Edges Lower to $7.72 as Shares Test Support Above $7.33Option Breadth - careplusvn.com
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Cormedix Stock Price Forecast. Should You Buy CRMD? - StockInvest.us
CorMedix Inc (NASDAQ: CRMD) Share Price, CRMD Stock News, CRMD Share Price & Updates - kalkine.ca
CorMedix Inc. (CRMD) Stock Analysis: Biotech Innovator With A 97.69% Potential Upside - DirectorsTalk Interviews
CorMedix (CRMD) Down -1.15% — 3 Warning Signs Investors Should See 2026-09-17Small Cap Breakouts - careplusvn.com
Why Did CRMD Stock Tumble Over 11% Today? - Stocktwits
CorMedix at Wells Fargo 21st annual healthcare conference: growth, risk By Investing.com - Investing.com Canada
CorMedix at Wells Fargo 21st annual healthcare conference: growth, risk By Investing.com - Investing.com UK
CorMedix Inc (NASDAQ:CRMD) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged - finance.yahoo.com
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet - finance.yahoo.com
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet - Zacks Investment Research
Bank of New York Mellon Corp Takes Position in CorMedix Inc $CRMD - MarketBeat
The Technical Signals Behind (CRMD) That Institutions Follow - Stock Traders Daily
243,232 Shares in CorMedix Inc $CRMD Purchased by Empowered Funds LLC - MarketBeat
CorMedix (CRMD) COO holds 270K shares after cost-covering share withholding - Stock Titan
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference - finance.yahoo.com
CorMedix will meet investors in Boston for a Wells Fargo chat - Stock Titan
Cormedix Inc Azioni (CRMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cormedix Inc Azioni (CRMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Janet Dillione | Director |
Jan 21 '26 |
Proposed Sale |
6.85 |
10,000 |
68,502 |
0 |
| Todisco Joseph | Chief Executive Officer |
Jan 16 '26 |
Option Exercise |
3.38 |
29,585 |
99,997 |
521,664 |
| Lefkowitz Steven W | Director |
Jan 12 '26 |
Option Exercise |
5.63 |
15,000 |
84,450 |
95,498 |
| DUNTON ALAN W | Director |
Dec 30 '25 |
Option Exercise |
4.03 |
20,000 |
80,600 |
60,250 |
| DUNTON ALAN W | Director |
Dec 30 '25 |
Sale |
13.00 |
20,000 |
260,000 |
40,250 |
| Alan Dunton | Director |
Dec 30 '25 |
Proposed Sale |
12.97 |
20,000 |
259,400 |
0 |
| Todisco Joseph | Chief Executive Officer |
Dec 18 '25 |
Option Exercise |
4.43 |
30,000 |
132,900 |
539,496 |
| Todisco Joseph | Chief Executive Officer |
Dec 18 '25 |
Sale |
12.00 |
30,000 |
360,000 |
509,496 |
| Joseph Todisco | Officer |
Dec 18 '25 |
Proposed Sale |
11.97 |
30,000 |
359,149 |
0 |
| Dillione Janet | Director |
Dec 09 '25 |
Option Exercise |
7.82 |
34,000 |
265,900 |
82,473 |
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):